Digital therapeutics firm Click on Therapeutics introduced Wednesday it should purchase the belongings of Higher Therapeutics, developer of a software-based therapy for diabetes. Click on, which didn’t disclose how a lot it’s paying for the belongings, hopes to adapt Higher’s tech to be used alongside GLP-1 medicines.
Higher Therapeutics introduced in March that it was delisting from the Nasdaq inventory change and shutting down operations because it sought strategic alternate options. The corporate had been, since final 12 months, trying to find methods to remain afloat as its money reserves dwindled.
Final, 12 months, Higher acquired Meals and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral remedy and had been proven to cut back A1c ranges in individuals with kind 2 diabetes. Nonetheless, the corporate has been unable to ramp up vital business traction. Higher additionally had a pipeline of different merchandise concentrating on cardiometabolic circumstances, and had made early claims about the advantages of AspyreRx in individuals taking GLP-1s for diabetes administration.
This text is unique to STAT+ subscribers
Unlock this text — and get further evaluation of the applied sciences disrupting well being care — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
View All Plans